No Abstract BioWorld International CorrespondentPARIS - DBV Technologies, which specializes in the diagnosis and treatment of allergies, completed a series B financing in which it raised €6 million (US$7.9 million) from one new and one existing investor.

LONDON - UK biotech needs to find a new way of funding start-ups. Even before the current financial crisis, institutional investors had lost interest in the sector because returns are too long term and too uncertain. (BioWorld International)